| US biopharmaceutical finance and the sustainability of the biotech business model W Lazonick, Ö Tulum Research Policy 40 (9), 1170-1187, 2011 | 329 | 2011 |
| Apple's changing business model: What should the world's richest company do with all those profits? W Lazonick, M Mazzucato, Ö Tulum Accounting Forum 37 (4), 249-267, 2013 | 96 | 2013 |
| US pharma's financialized business model W Lazonick, M Hopkins, K Jacobson, ME Sakinç, Ö Tulum Institute for New Economic Thinking Working Paper Series, 2017 | 83 | 2017 |
| Financialized corporations in a national innovation system: the US pharmaceutical industry Ö Tulum, W Lazonick International Journal of Political Economy 47 (3-4), 281-316, 2018 | 80 | 2018 |
| The innovative enterprise and the developmental state: Toward an economics of organizational success W Lazonick Institute for New Economic Thinking Annual 2011 Conference, Bretton Woods …, 2011 | 64 | 2011 |
| US biopharmaceutical finance and the sustainability of the biotech boom W Lazonick, Ö Tulum | 27 | 2010 |
| Financialization of the US pharmaceutical industry W Lazonick, Ö Tulum, M Hopkins, ME Sakinç, K Jacobson Institute for New Economic Thinking 2, 2019 | 22 | 2019 |
| Skill development and sustainable prosperity: cumulative and collective careers versus skill-biased technical change W Lazonick, P Moss, H Salzman, Ö Tulum Institute for New Economic Thinking Working Paper Series, 2014 | 15 | 2014 |
| Skill development and sustainable prosperity: collective and cumulative careers versus skill-biased technical change W Lazonick, P Moss, H Salzman, Ö Tulum Institute for New Economic Thinking Working Group on the Political Economy …, 2014 | 15 | 2014 |
| US Pharma's Business Model: Why it is broken, and how it can be fixed W Lazonick, M Hopkins, K Jacobson, ME Sakinç, Ö Tulum The Routledge Handbook of the Political Economy of Science, 83-100, 2017 | 14 | 2017 |
| Life Sciences? How ‘Maximizing Shareholder Value’increases drug prices, restricts access, and stifles innovation W Lazonick, M Hopkins, K Jacobson, ME Sakinç, Ö Tulum UN Secretary-General’s High-Level Panel on Access to Medicines. https …, 2016 | 9 | 2016 |
| From financialisation to innovation in UK Big pharma: AstraZeneca and GlaxoSmithKline Ö Tulum, A Andreoni, W Lazonick Elements in Reinventing Capitalism, 2022 | 7 | 2022 |
| Innovation and financialization in the us biopharmaceutical industry Ö Tulum Unpublished doctoral dissertation, Faculty of Economics, University of …, 2018 | 7 | 2018 |
| Boston’s Biotech Boom: A New “Massachusetts Miracle”?’ W Lazonick, E March, Ö Tulum UMass Lowell Center for Industrial Competitiveness Working Paper’, May …, 2007 | 7 | 2007 |
| Boston’s Biotech Boom W Lazonick, E March, Ö Tulum UMass Lowell Center for Industrial Competitiveness Working Paper, May, 2007 | 5 | 2007 |
| ways to eradicate the corporate disease that is worsening the Covid-19 pandemic W Lazonick, M Hopkins, K Jacobson, L Palladino, M Erdum Sakinc, ... Institute for New Economic Thinking. https://www. ineteconomics. org …, 4 | 5 | 4 |
| Sick with “shareholder value”: US pharma’s financialized business model during the pandemic W Lazonick, Ö Tulum Competition & Change, 10245294231210975, 2022 | 4 | 2022 |
| Impact of a new price support policy on the Turkish hazelnut industry AD Spaulding, O Tulum, S Saghaian, G Özertan VII International Congress on Hazelnut 845, 795-800, 2008 | 4 | 2008 |
| Productivity and profitability of Turkish hazelnut production O Tulum VII International Congress on Hazelnut 845, 733-738, 2008 | 3 | 2008 |
| Political economy, productivity and profitability of Turkish hazelnut production O Tulum University of Massachusetts Lowell, 2008 | 2 | 2008 |
William LazonickUMass Lowell; The Academic-Industry Research NetworkVerified email at uml.edu
